[go: up one dir, main page]

WO2018190638A1 - Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max - Google Patents

Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max Download PDF

Info

Publication number
WO2018190638A1
WO2018190638A1 PCT/KR2018/004253 KR2018004253W WO2018190638A1 WO 2018190638 A1 WO2018190638 A1 WO 2018190638A1 KR 2018004253 W KR2018004253 W KR 2018004253W WO 2018190638 A1 WO2018190638 A1 WO 2018190638A1
Authority
WO
WIPO (PCT)
Prior art keywords
corneal
extract
composition
eye
rat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/004253
Other languages
English (en)
Korean (ko)
Inventor
김경아
강태겸
강석우
오상록
정상훈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Science and Technology KIST
Original Assignee
Korea Institute of Science and Technology KIST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Science and Technology KIST filed Critical Korea Institute of Science and Technology KIST
Publication of WO2018190638A1 publication Critical patent/WO2018190638A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Definitions

  • corneal surface is directly exposed to the outside, making it vulnerable to trauma and scratches.
  • corneal damage may occur frequently in patients suffering from diseases such as dry eye syndrome caused by a significant decrease in tear protection due to the lack of tears. If the cornea is damaged, irritation symptoms such as irritation, foreign body or dryness, as well as if the damage is severe may develop keratitis.
  • irritation symptoms such as irritation, foreign body or dryness, as well as if the damage is severe may develop keratitis.
  • Figure 2 shows the tear film breakdown time measurement results in the corneal injury animal model induced by BAC according to an experimental example of the present specification ( *** p ⁇ 0.001 ).
  • the techniques disclosed herein provide a non-therapeutic use of a soybean extract for use in the prevention, amelioration and / or treatment of corneal disease or corneal injury.
  • compositions disclosed herein have the effect of preventing corneal damage, preventing minor corneal damage from worsening, or ameliorating or treating a damaged cornea.
  • Dry eye syndrome is an eye disorder in which the eye's surface is damaged, the eye gets cold and there are irritating symptoms such as irritation, foreign body, and dryness due to lack of tears, excessive evaporation of tears, or poor balance of tear components.
  • Say Rat eye extract according to the present disclosure has the effect of increasing the stability of the tear film and inhibiting corneal damage and protecting the surface of the cornea to prevent, improve or treat dry eye syndrome.
  • Rats In the old document ⁇ Primary herb '', rat eye is "warm in nature, sweet in taste, and no poison. It is better to use light and soft, small soybeans (dungdue) as a medicine. Inhibits, activates blood circulation and detoxify ". Rats have long been used to prevent neuralgia, kidney disease and senile dementia. Rats have not only higher isoflavones than yellow soybeans, but also cyanidin-3-glucosides among glycidin and anthocyanin, which have excellent antioxidant effects on the seedlings. It is known to be effective in the prevention and treatment of cerebrovascular and heart diseases.
  • the extraction method of step 1) includes hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction.
  • the extraction may be performed one to five times by an ultrasonic extraction method.
  • the extraction temperature is preferably 10 ° C to 100 ° C and more preferably room temperature, but is not limited thereto.
  • the extraction time is preferably 1 hour to 7 days, more preferably 3 to 7 days, but is not limited thereto.
  • the organic solvent of step 4) is preferably normal-hexane, methylene chloride, ethyl acetate or normal-butanol, but is not limited thereto.
  • the fraction of step 4) is obtained by suspending the rat bean extract in water and then systematically fractionating the mixture into normal-hexane, methylene chloride, ethyl acetate, normal-butanol and water, and then extracting the normal-hexane fraction, methylene chloride fraction, and ethyl acetate fraction. It is preferably one of the normal-butanol fraction or the water fraction, more preferably methylene chloride fraction, but is not limited thereto.
  • the fraction can be obtained by repeating the fractionation process 1 to 5 times, preferably three times from the rat eye extract, preferably concentrated under reduced pressure after the fraction is not limited thereto.
  • compositions of the present invention may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. .
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, sucrose, and the like in the composition of the present invention. (sucrose), lactose (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the health functional beverage composition of the present invention is not particularly limited to other ingredients other than containing rat bean extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
  • natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • the corneal damage was observed by using a fluorescent dye (Fluorescein sodium salt). Fluorescein staining stains the substrate at the site where the corneal epithelial cell is missing. 1 ⁇ L of 0.1% sodium fluorescein was dropped into the eye of the experimental animal, and the extent of corneal cell damage was photographed using a slit-lamp.
  • fluorescent dye Fluorescein sodium salt
  • Tear film destruction time is assessed to the extent of damage to corneal epithelial cells. Tear film destruction time was measured using a fluorescein sodium salt. After 1 ⁇ L of 0.1% sodium fluorescein was dropped into the eye of the experimental animal, the time for the disappearance of the fluorescent dye was measured.
  • TUNEL Analysis (Terminal deoxynucleotidyl transferase dUTP nick end labeling, TUNEL assay)
  • Paraoxin benzoic acid methyl was added to sterile purified water, heated to dissolve, and cooled to dissolve the rat eye extract.
  • Carbopol 934 was added thereto, mixed with a high speed stirrer, dispersed, and left to stand to remove air.
  • triethanolamine was added drop by drop while being careful not to let air enter, thereby preparing an eye drop.
  • composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • the granules may be prepared and used for preparing a health food composition according to a conventional method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne : une composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max en tant que principe actif ; et une composition de complément alimentaire pour soulager une lésion cornéenne, contenant un extrait de glycine max en tant que principe actif. L'extrait de glycine max a des effets d'inhibition des dégâts des cellules de la cornée, de protection des cellules de la cornée, et de prévention, de soulagement ou de traitement du syndrome de l'œil sec et de l'abrasion de la cornée.
PCT/KR2018/004253 2017-04-12 2018-04-11 Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max Ceased WO2018190638A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170047303A KR101838142B1 (ko) 2017-04-12 2017-04-12 쥐눈이콩 추출물을 포함하는 각막 질환의 예방 또는 치료용 조성물
KR10-2017-0047303 2017-04-12

Publications (1)

Publication Number Publication Date
WO2018190638A1 true WO2018190638A1 (fr) 2018-10-18

Family

ID=61660343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/004253 Ceased WO2018190638A1 (fr) 2017-04-12 2018-04-11 Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max

Country Status (2)

Country Link
KR (1) KR101838142B1 (fr)
WO (1) WO2018190638A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103454A1 (fr) * 2023-11-15 2025-05-22 博太生技医药股份有限公司 Procédé d'amélioration du syndrome de l'œil sec à l'aide d'un extrait à l'éthanol de graines de soja et d'une combinaison de celui-ci avec un distillat à l'éthanol de graines de soja

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101838142B1 (ko) * 2017-04-12 2018-03-14 한국과학기술연구원 쥐눈이콩 추출물을 포함하는 각막 질환의 예방 또는 치료용 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100832240B1 (ko) * 2007-04-11 2008-05-28 경상대학교산학협력단 검정콩 껍질로부터 추출한 안토시아닌을 함유하는 창상치료용 의약 조성물
KR20090019396A (ko) * 2007-08-21 2009-02-25 우석대학교 산학협력단 쥐눈이콩 물추출물을 포함하는 알레르기성 질환의 예방 및치료용 약학조성물
KR20110004370A (ko) * 2008-02-25 2011-01-13 내셔널 양밍 유니버시티 안질환을 치료하기 위한 검은 콩의 용도
KR20130055405A (ko) * 2011-11-18 2013-05-28 인산죽염촌 주식회사 눈 세정제 조성물 및 이의 제조방법
WO2017030410A1 (fr) * 2015-08-19 2017-02-23 한국생명공학연구원 Composition pour la prévention ou le traitement du syndrome métabolique ou pour anti-oxydation contenant des extraits de feuille de haricot noir et des glycosides de flavonol isolés à partir de ces derniers comme principes actifs
KR101835227B1 (ko) * 2016-09-02 2018-03-08 동의대학교 산학협력단 서목태 추출물을 포함하는 안질환 예방 또는 치료용 조성물
KR101838142B1 (ko) * 2017-04-12 2018-03-14 한국과학기술연구원 쥐눈이콩 추출물을 포함하는 각막 질환의 예방 또는 치료용 조성물

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100832240B1 (ko) * 2007-04-11 2008-05-28 경상대학교산학협력단 검정콩 껍질로부터 추출한 안토시아닌을 함유하는 창상치료용 의약 조성물
KR20090019396A (ko) * 2007-08-21 2009-02-25 우석대학교 산학협력단 쥐눈이콩 물추출물을 포함하는 알레르기성 질환의 예방 및치료용 약학조성물
KR20110004370A (ko) * 2008-02-25 2011-01-13 내셔널 양밍 유니버시티 안질환을 치료하기 위한 검은 콩의 용도
KR20130055405A (ko) * 2011-11-18 2013-05-28 인산죽염촌 주식회사 눈 세정제 조성물 및 이의 제조방법
WO2017030410A1 (fr) * 2015-08-19 2017-02-23 한국생명공학연구원 Composition pour la prévention ou le traitement du syndrome métabolique ou pour anti-oxydation contenant des extraits de feuille de haricot noir et des glycosides de flavonol isolés à partir de ces derniers comme principes actifs
KR101835227B1 (ko) * 2016-09-02 2018-03-08 동의대학교 산학협력단 서목태 추출물을 포함하는 안질환 예방 또는 치료용 조성물
KR101838142B1 (ko) * 2017-04-12 2018-03-14 한국과학기술연구원 쥐눈이콩 추출물을 포함하는 각막 질환의 예방 또는 치료용 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103454A1 (fr) * 2023-11-15 2025-05-22 博太生技医药股份有限公司 Procédé d'amélioration du syndrome de l'œil sec à l'aide d'un extrait à l'éthanol de graines de soja et d'une combinaison de celui-ci avec un distillat à l'éthanol de graines de soja

Also Published As

Publication number Publication date
KR101838142B1 (ko) 2018-03-14

Similar Documents

Publication Publication Date Title
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2016153211A2 (fr) Procédé de préparation d'extrait d'écorce d"agrumes et composition pour prévenir, soulager ou traiter une lésion hépatique
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
KR101734896B1 (ko) 감나무 추출물을 유효성분으로 포함하는 각막 손상의 예방, 개선 또는 치료용 조성물
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
WO2021080129A1 (fr) Composition pour renforcer la barrière cutanée et soulager la dermatite atopique, comprenant de l'hydrangénol ou de la phyllodulcine en tant que principe actif
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
WO2020235828A1 (fr) Composition pour l'inhibition d'ostéoclastes contenant un extrait d'agastache rugosa en tant que principe actif, et son utilisation
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2016056781A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait d'artemisia umbelliformis
WO2015174636A1 (fr) Composition pour la prévention et le traitement de l'infertilité masculine, contenant un extrait d'herbes mixtes en tant qu'ingrédient actif et utilisation de celle-ci
WO2013069934A1 (fr) Composition pour traiter et prévenir l'obésité, contenant de l'extrait d'agropyre comme principe actif
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2016056780A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait de scutellaria alpina
WO2014073855A1 (fr) Composition comprenant un extrait de substance naturelle ou une fraction associée en tant que principe actif pour la prévention ou le traitement de l'insuffisance rénale aiguë
WO2017111429A1 (fr) Composition pour le traitement du syndrome de sécheresse oculaire, contenant un extrait d'airelle noire en tant que substance active
WO2010008150A2 (fr) Composition pour prévenir ou traiter l'ostéoporose qui contient comme principe actif un mélange d'extraits de saururus chinensis et de scutellaria baicalensis
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2022270760A1 (fr) Méthode de traitement de la stéatohépatite non alcoolique par la co-administration d'un dérivé de la curcumine et d'un inhibiteur du récepteur de tgf-β
WO2013022178A1 (fr) Composition pour prévention et traitement de l'obésité contenant un principe actif sous la forme d'un extrait de préparation végétale mélangée à base de lonicera japonica et d'aurantii nobilis pericarpium fermenté ou non fermenté, et son utilisation
WO2018106009A1 (fr) Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière
WO2016003120A1 (fr) Composition de blanchiment comprenant un extrait de scutellaria alpina
WO2015152653A1 (fr) Composition comprenant un extrait de feuilles de génépi blanc

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18784549

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18784549

Country of ref document: EP

Kind code of ref document: A1